國立虎尾科技大學 |

Glutamate and Neuropsychiatric Disorders = Current and Emerging Treatments /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Glutamate and Neuropsychiatric Disorders/ edited by Zoran M. Pavlovic.
其他題名:	Current and Emerging Treatments /
其他作者:	Pavlovic, Zoran M.
面頁冊數:	XXXV, 600 p. 43 illus., 40 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Neurology. -
電子資源:	https://doi.org/10.1007/978-3-030-87480-3
ISBN:	9783030874803

Glutamate and Neuropsychiatric Disorders = Current and Emerging Treatments /
Glutamate and Neuropsychiatric DisordersCurrent and Emerging Treatments /[electronic resource] :edited by Zoran M. Pavlovic. - 1st ed. 2022. - XXXV, 600 p. 43 illus., 40 illus. in color.online resource.

Treatments Against Glutamatergic Excitotoxicity in Ischemic Stroke -- Definitions and Concepts of Stress -- Role of Glutamatergic Neurotransmission in the Pathophysiology of Stress-Related Disorders and Chronic Stress Response -- Current Glutamatergic Treatments and Future Directions for Glutamate-Based Management of Chronic Stress and Stress-Related Disorders -- The Role of the Glutamate System in Posttraumatic Stress Disorder and Glutamate-Based Treatments -- Glutamate in Migraine Neurobiology and Treatment -- Astrocyte Glutamate Transporter EAAT2 in Alzheimer Dementia -- The Glutamatergic System as a Target for the Development of New Pharmacological Treatments of Bipolar Disorder -- CNS Glutamate in Impulsive Aggression -- Glutamatergic Treatments for Parkinsons' Disease -- The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression -- Glutamate-Based Treatment for Amyotrophic Lateral Sclerosis/Motor Neuron Disease -- Modulation of Glutamate for Chronic Pain Management -- Pharmacological Role of Glutamate Transporters in Substance Use Disorders -- Glutamate in Multiple Sclerosis: From Pathophysiology to Treatments -- The Role of Glutamate Dysregulation in the Etiology of ADHD -- Glutamate, Glutamatergic Drugs and Schizophrenia -- Glutamate and Epilepsy: An Insight from Temporal Lobe Epilepsy -- Glutamate Function in Anxiety Disorders and OCD: Evidence from Clinical and Translational Studies -- Modulators of Glutamatergic Signaling as Potential Treatments for Autism Spectrum Disorders.

This volume provides a comprehensive overview of recent advances in targeting glutamate signaling for the treatment of major psychiatric and neurological disorders. It draws on the latest findings in glutamate neurobiology and offers valuable insights into the application of translational principles in neuroscience drug discovery and development. In each chapter, glutamate as a neurotransmitter, its receptors and transporters, and their interplay with other neurotransmitters and neurotrophic factors, are discussed in the context of a specific, highly prevalent and disabling CNS disease. Most recent and detailed information is provided on Ischemic Stroke, Chronic Stress, Major Depressive Disorder, Bipolar Disorder, Autism Spectrum Disorders (ASD), Posttraumatic Stress Disorder (PTSD), Alzheimer’s Dementia, Schizophrenia, Impulsive Aggression, Substance Use Disorders (SUD), Amyotrophic Lateral Sclerosis (ALS), Chronic Pain, Multiple Sclerosis, Parkinson’s Disease, Attention Deficit Hyperactivity Disorder (ADHD), Migraine, Epilepsy and Anxiety disorders. Moreover, the book includes an extensive overview of glutamatergic treatments already available on the market, and those which are currently in pharmaceutical drug development pipelines. The primary beneficiaries will be neurology and psychiatry specialists and residents, neuroscientists, neuropharmacologists, pharmaceutical industry and clinical research organization professionals, academics, and clinicians working with psychiatric and neurological patients with comorbidities such as cardiologists, pulmonologists, and endocrinologists. This book will also appeal to psychiatry and neurology subspecialists and clinicians working in neuroscience labs seeking an easy-to-understand yet comprehensive overview of contemporary evidence-based clinical insights backed by basic science (preclinical) research evidence. Given its scope, the book is also a unique and indispensable resource for both preclinical and clinical neuroscientists, medical advisors, and clinical research specialists in the pharmaceutical industry. In addition, it will appeal to neuroscience and neuropsychopharmacology students and guide them through the complexities of glutamate involvement in the pathophysiology of the most common debilitating brain diseases with high unmet medical needs.

ISBN: 9783030874803

Standard No.: 10.1007/978-3-030-87480-3doiSubjects--Topical Terms:

593894
Neurology.

LC Class. No.: RC321-580

Dewey Class. No.: 612.8

Glutamate and Neuropsychiatric Disorders = Current and Emerging Treatments /
LDR:05294nam a22003975i 4500 001 1092589
003 DE-He213
005 20220410015621.0
007 cr nn 008mamaa
008 221228s2022 sz | s |||| 0|eng d
020 $a 9783030874803 $9 978-3-030-87480-3
024 7 $a 10.1007/978-3-030-87480-3 $2 doi
035 $a 978-3-030-87480-3
050 4 $a RC321-580
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
072 7 $a PSAN $2 thema
082 0 4 $a 612.8 $2 23
245 1 0 $a Glutamate and Neuropsychiatric Disorders $h [electronic resource] : $b Current and Emerging Treatments / $c edited by Zoran M. Pavlovic.
250 $a 1st ed. 2022.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a XXXV, 600 p. 43 illus., 40 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Treatments Against Glutamatergic Excitotoxicity in Ischemic Stroke -- Definitions and Concepts of Stress -- Role of Glutamatergic Neurotransmission in the Pathophysiology of Stress-Related Disorders and Chronic Stress Response -- Current Glutamatergic Treatments and Future Directions for Glutamate-Based Management of Chronic Stress and Stress-Related Disorders -- The Role of the Glutamate System in Posttraumatic Stress Disorder and Glutamate-Based Treatments -- Glutamate in Migraine Neurobiology and Treatment -- Astrocyte Glutamate Transporter EAAT2 in Alzheimer Dementia -- The Glutamatergic System as a Target for the Development of New Pharmacological Treatments of Bipolar Disorder -- CNS Glutamate in Impulsive Aggression -- Glutamatergic Treatments for Parkinsons' Disease -- The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression -- Glutamate-Based Treatment for Amyotrophic Lateral Sclerosis/Motor Neuron Disease -- Modulation of Glutamate for Chronic Pain Management -- Pharmacological Role of Glutamate Transporters in Substance Use Disorders -- Glutamate in Multiple Sclerosis: From Pathophysiology to Treatments -- The Role of Glutamate Dysregulation in the Etiology of ADHD -- Glutamate, Glutamatergic Drugs and Schizophrenia -- Glutamate and Epilepsy: An Insight from Temporal Lobe Epilepsy -- Glutamate Function in Anxiety Disorders and OCD: Evidence from Clinical and Translational Studies -- Modulators of Glutamatergic Signaling as Potential Treatments for Autism Spectrum Disorders.
520 $a This volume provides a comprehensive overview of recent advances in targeting glutamate signaling for the treatment of major psychiatric and neurological disorders. It draws on the latest findings in glutamate neurobiology and offers valuable insights into the application of translational principles in neuroscience drug discovery and development. In each chapter, glutamate as a neurotransmitter, its receptors and transporters, and their interplay with other neurotransmitters and neurotrophic factors, are discussed in the context of a specific, highly prevalent and disabling CNS disease. Most recent and detailed information is provided on Ischemic Stroke, Chronic Stress, Major Depressive Disorder, Bipolar Disorder, Autism Spectrum Disorders (ASD), Posttraumatic Stress Disorder (PTSD), Alzheimer’s Dementia, Schizophrenia, Impulsive Aggression, Substance Use Disorders (SUD), Amyotrophic Lateral Sclerosis (ALS), Chronic Pain, Multiple Sclerosis, Parkinson’s Disease, Attention Deficit Hyperactivity Disorder (ADHD), Migraine, Epilepsy and Anxiety disorders. Moreover, the book includes an extensive overview of glutamatergic treatments already available on the market, and those which are currently in pharmaceutical drug development pipelines. The primary beneficiaries will be neurology and psychiatry specialists and residents, neuroscientists, neuropharmacologists, pharmaceutical industry and clinical research organization professionals, academics, and clinicians working with psychiatric and neurological patients with comorbidities such as cardiologists, pulmonologists, and endocrinologists. This book will also appeal to psychiatry and neurology subspecialists and clinicians working in neuroscience labs seeking an easy-to-understand yet comprehensive overview of contemporary evidence-based clinical insights backed by basic science (preclinical) research evidence. Given its scope, the book is also a unique and indispensable resource for both preclinical and clinical neuroscientists, medical advisors, and clinical research specialists in the pharmaceutical industry. In addition, it will appeal to neuroscience and neuropsychopharmacology students and guide them through the complexities of glutamate involvement in the pathophysiology of the most common debilitating brain diseases with high unmet medical needs.
650 2 4 $a Neurology. $3 593894
650 1 4 $a Neuroscience. $3 569964
650 0 $a Psychiatry. $3 585488
650 0 $a Neuropharmacology. $3 677629
650 0 $a Pharmacology. $3 583819
650 0 $a Neuropsychology. $3 556286
650 0 $a Neurology . $3 1253459
650 0 $a Neurosciences. $3 593561
700 1 $a Pavlovic, Zoran M. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1400382
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030874797
776 0 8 $i Printed edition: $z 9783030874810
776 0 8 $i Printed edition: $z 9783030874827
856 4 0 $u https://doi.org/10.1007/978-3-030-87480-3
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)